. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma . J Clin Oncol 2006 ; 24 : 1188 – 1194 . 17. Spitler LE Grossbard ML Ernstoff MS . Adjuvant therapy of stage III and IV malignant
Search Results
Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett
Weeks J . Controversies regarding laparoscopic colectomy for malignant diseases . Curr Opin Gen Surg 1994 : 208 – 213 . 65 Sun W Haller DG . Adjuvant therapy of colon cancer . Semin Oncol 2005 ; 32 : 95 – 102 . 66 Baddi L
Sandra O. Gollnick
improved response when we used PDT lysate.” These vaccines seemed to inhibit the growth of both new and established tumors, suggesting their clinical potential as an adjuvant therapy. The generation of effective vaccines depends on active metabolism, at
Lee S. Schwartzberg and Sarah L. Blair
/carboplatin/trastuzumab. 5 years of tamoxifen reduced recurrences in patients aged 65 years and older. 13 “Based on these data, for the ‘younger’ older woman completing 5 years of adjuvant therapy who is at risk for recurrence, an additional 5 years of treatment is
Presenter: William J. Gradishar
Breast cancer mortality is approximately half of what it was in 1980 due to aggressive screening, combination adjuvant therapies, and the emergence of effective targeted agents for the metastatic setting. “We anticipate that as data emerge from
Presenter: Maura L. Gillison
(ClinicalTrials.gov identifier: NCT03952585 ). “Those that exceed the landmark PFS and MDADI scores could move forward in a randomized phase III trial,” she said. Can Adjuvant Therapy Be Altered After Primary Surgical Resection? ECOG 3311 was the first
Daniel Morgensztern and Ramaswamy Govindan
; 4 : 35 – 44 . 22. Keller SM Adak S Wagner H . A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group . N Engl J Med 2000
Benjamin E. Greer and Wui-Jin Koh
extension and N2 as gross disease, Dr. Koh noted. He stated that selecting patients for adjuvant therapy is challenging. Rather than look at the total number of nodes, he suggested using a ratio of the number of positive nodes per side divided by the number
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021
Featured Updates to the NCCN Guidelines
William J. Gradishar, Meena S. Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Steven J. Isakoff, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice Lyons, Jennifer Matro, Ingrid A. Mayer, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar
Systemic Therapy In patients with early-stage breast cancer, systemic adjuvant therapy is administered to reduce risk of breast cancer recurrence. The decision is often based on individual risk of relapse and predicted sensitivity to treatment (eg
Omalkhair Abulkhair, Nagi Saghir, Lobna Sedky, Ahmed Saadedin, Heba Elzahwary, Neelam Siddiqui, Mervat Al Saleh, Fady Geara, Nuha Birido, Nadia Al-Eissa, Sana Al Sukhun, Huda Abdulkareem, Menar Mohamed Ayoub, Fawaz Deirawan, Salah Fayaz, Alaa Kandil, Sami Khatib, Mufid El-Mistiri, Dorria Salem, El Siah Hassan Sayd, Mohammed Jaloudi, Mohammad Jahanzeb, and William I. Gradishar
studies, adjuvant therapy includes chemotherapy, targeted therapy with trastuzumab, and hormonal therapy. 13 – 15 In countries with limited resources, anthracyclines and taxanes are the most commonly used drugs, either in combination or sequentially